๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Fuzhou
Clinical trial register · China

Clinical Trials in Fuzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca62 First Affiliated Hospital of Fujian Medical University45 Merck Sharp & Dohme LLC39 Fujian Medical University Union Hospital39 Fujian Cancer Hospital35
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Fuzhou

1018 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Active, closed
Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma
NCT05471843Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma (MCL), Relapsed Mantle Cell Lymphoma
DrugSonrotoclax
BeiGene
Phase 1/2
125
Hefei, Beijing, Fuzhou, Guangzhou, Jiangmen, Nanning, Guiyang, Haikou
2022-09-05
Not yet open
Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes
NCT05524974Locally Advanced Gastric Cancer
Fujian Medical University
Phase 2
203
Fuzhou
2022-09-01
Active, closed
A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs
NCT05459844Neuroendocrine Tumors
DrugsLutetium[177Lu] Oxodotreotide·Octreotide LAR
Sinotau Pharmaceutical Group
Phase 3
196
Beijing, Fuzhou, Xiamen, Guangzhou, Zhengzhou, Wuhan, Nanjing, Changchun
2022-08-31
Recruiting
China HeadAche DIsorders RegiStry
NCT05334927Headache Disorders, Primary, Migraine, New Daily Persistent Headache, Medication Overuse Headache
DrugEptinezumab
Beijing Tiantan Hospital
Observational
10,000
Anqing, Wuhu, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Shenzhen
2022-08-29
Active, closed
Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials
NCT05492578Dermatitis Atopic
DrugAmlitelimab
Sanofi
Phase 2/3
1,856
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Nanchang
2022-08-22
Recruiting
A Real-world Study of Camrelizumab Combined With Apatinib Mesylate in Unresectable Hepatocellular Carcinoma
NCT05409482Hepatocellular Carcinoma
Meng Chao Hepatobiliary Hospital of Fujian Medical University
Observational
300
Fuzhou
2022-08-20
Recruiting
A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2-Positive/Negative Breast Cancer and Other Solid Tumors
NCT05461768Breast Cancer, Locally Advanced or Metastatic Solid Tumor
DrugBL-M07D1
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
348
Fuzhou, Dongguan, Guangdong, Zhengzhou, Wuhan, Jinan, Hangzhou
2022-08-09
Active, closed
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
NCT05261399Carcinoma, Non-Small-Cell Lung
DrugsSavolitinib·Osimertinib·Pemetrexed·Cisplatin
AstraZeneca
Phase 3
341
Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou
2022-08-03
Recruiting
Short-course Radiotherapy (5ร—6Gy/7Gy/8Gy) Followed by Neo-adjuvant Chemotherapy for Locally Advanced Rectal Cancer
NCT03466424Radiation Oncology, Rectal Cancer
Fujian Medical University Union Hospital
Observational
9
Fuzhou
2022-08-01
Active, closed
Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations
NCT05457257Metastatic Castration-resistant Prostate Cancer
DrugsAbiraterone acetate·Olaparib·Enzalutamide·Prednisone
AstraZeneca
Phase 4
43
Beijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2022-07-29
Active, closed
A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced or Metastatic Solid Tumors
NCT05502393Advanced Solid Tumors
DrugsJS107·Toripalimab·Oxaliplatin·Capecitabine
Shanghai Junshi Bioscience Co., Ltd.
Phase 1
133
Chizhou, Fuzhou, Wuwei, Guangzhou, Meizhou, Shijiazhuang, Wuhan, Harbin
2022-07-26
Active, closed
First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors
NCT05438329Advanced Solid Tumor
DrugsDB-1305/BNT325·Pumitamig
DualityBio Inc.
Phase 1/2
1,123
Bengbu, Hefei, Fuzhou, Lanzhou, Dongguan, Guangzhou, Guigang, Nanning
2022-07-19
Active, closed
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
NCT05296798Locally Advanced or Metastatic Breast Cancer
DrugsPhesgo·Giredestrant·Docetaxel·Paclitaxel
Hoffmann-La Roche
Phase 3
922
Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Fuzhou, Hangzhou
2022-07-18
Active, closed
A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)
NCT05460273Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Cancer
DrugDato-DXd
AstraZeneca
Phase 1/2
119
Beijing, Bengbu, Changchun, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou
2022-07-11
Active, closed
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
NCT05338970Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion
DrugPatritumab Deruxtecan
Daiichi Sankyo
Phase 3
586
Beijing, Changchun, Changsha, Chengdu, Chibi, Fuzhou, Guangzhou, Haidian
2022-07-08
Active, closed
To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer
NCT05365178HR-positive, HER2-negative Breast Neoplasms
DrugsTQB3616·Fulvestrant
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
432
Bengbu, Wuhu, Beijing, Chongqing, Fuzhou, Lanzhou, Wuwei, Guangzhou
2022-07-01
Active, closed
TAB014 Compared to Lucentisยฎ in Patients with Neovascular Age-related Macular Degeneration
NCT05461339Neovascular Age-related Macular Degeneration
DrugsLucentis·Ranibizumab
BioDlink Biopharm Co., Ltd.
Phase 3
488
Hefei, Beijing, Jilin City, Chongqing, Fuzhou, Guangzhou, Shantou, Shenzhen
2022-06-28
Recruiting
Down Sizing Strategy (HANGZHOU Solution) vs Standard Sizing Strategy TAVR in Bicuspid Aortic Stenosis (Type 0)
NCT05511792Aortic Stenosis With Bicuspid Valve
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
206
Fuzhou, Xiamen, Lanzhou, Guangzhou, Yulin, Zhengzhou, Changsha, Nanchang
2022-06-27
Active, closed
Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer
NCT05132075Non-Small Cell Lung Cancer
DrugsJDQ443·Docetaxel
Novartis Pharmaceuticals
Phase 3
95
Fuzhou, Guangzhou, Harbin, Changsha, Shengyang, Jinan, Hangzhou, Beijing
2022-06-15
Recruiting
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
NCT05405595Advanced/Metastatic Solid Tumors
DrugsADG126·Pembrolizumab
Adagene Inc
Phase 1/2
186
Fuzhou, Guangzhou, Hong Kong
2022-06-15
Active, closed
A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naรฏve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer
NCT05047250Non-Small Cell Lung Cancer
DrugAtezolizumab
Hoffmann-La Roche
Phase 3
60
Beijing, Changsha, Chongqing, Fuzhou, Hangzhou, Hefei, Linyi, Nanjing
2022-06-14
Recruiting
Clinical Outcomes of Indocyanine Green Tracer Using in Laparoscopic Gastrectomy With Lymph Node Dissection for Remnant Gastric Cancer
NCT05618821Gastric Cancer
Fujian Medical University
Phase 2
68
Fuzhou
2022-06-03
Active, closed
Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer
NCT05195632Non-Small Cell Lung Cancer
DrugsBinimetinib·Encorafenib
Pierre Fabre Medicament
Phase 2
63
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou
2022-06-02
Recruiting
Effect of HPV Integration on Prognosis of Young Women With CIN2 in China
NCT05282095Cervical Intraepithelial Neoplasia, HPV Infection, Virus Integration, HSIL, High Grade Squamous Intraepithelial Lesions
Fujian Maternity and Child Health Hospital
Observational
300
Fuzhou, Longyan, Ningde, Putian, Sanming, Zhangzhou, Lanzhou, Shenzhen
2022-06-01
Recruiting
Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma
NCT05515315Immunotherapy Esophagus Cancer
DrugsNedaplatin·Albumin paclitaxel·Tislelizumab
Fuzhou General Hospital
Phase 2
93
Fuzhou
2022-05-31
Active, closed
A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer
NCT05297890Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
DrugLorlatinib
CStone Pharmaceuticals
Phase 2
70
Guangzhou, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Hangzhou
2022-05-27
Active, closed
A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer
NCT05353257Limited-Stage Small Cell Lung Cancer
DrugsCarboplatin/cisplatin-etoposide·Serplulimab
Shanghai Henlius Biotech
Phase 3
511
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Shenzhen, Guilin
2022-05-17
Recruiting
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
NCT05294731B-cell Malignancy, Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
BeiGene
Phase 1/2
146
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Nanyang
2022-05-06
Active, closed
A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
NCT05171647Non-Hodgkin Lymphoma
DrugsMosunetuzumab·Polatuzumab Vedotin·Tocilizumab·Rituximab
Hoffmann-La Roche
Phase 3
208
Chengdu, Fuzhou, Guangzhou, Tianjin, Wuhan, Zhengzhou
2022-04-25
Recruiting
Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
NCT05288205KRAS P.G12C, Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma
DrugsJAB-3312·Glecirasib
Allist Pharmaceuticals, Inc.
Phase 1/2
240
Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Shenzhen, Harbin, Zhengzhou
2022-04-14
Active, closed
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)
NCT05239741Colorectal Neoplasms
DrugsLeucovorin·Irinotecan·Cetuximab·Ivonescimab
Merck Sharp & Dohme LLC
Phase 3
100
Beijing, Tianjin, Chongqing, Fuzhou, Guangzhou, Shantou, Nanning, Harbin
2022-04-02
Recruiting
Study of the Effectiveness and Safety of Daunorubicin /Idarubicin ยฑ Silibinin in Treating Newly Diagnosed AML (Non-M3).
NCT07561892Acute Myeloid Leukemia, Newly Diagnosed, Chemotherapy Effect
Fujian Medical University Union Hospital
Phase 4
100
Fuzhou
2022-04-01
Recruiting
Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial
NCT05340491Nasopharyngeal Carcinoma
DrugToripalimab
Sun Yat-sen University
Phase 3
212
Guangzhou, Beijing, Chengdu, Fuzhou, Guiyang, Hangzhou, Nanchang, Nanning
2022-04-01
Active, closed
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
NCT05301842Hepatocellular Carcinoma
DrugsTremelimumab·Lenvatinib·Durvalumab
AstraZeneca
Phase 3
760
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou
2022-03-28
Recruiting
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT04928846Non Small Cell Lung Cancer
DrugsTelisotuzumab vedotin·Docetaxel
AbbVie
Phase 3
768
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shantou, Zhanjiang
2022-03-25
Active, closed
Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)
NCT05224141Small Cell Lung Carcinoma
DrugsEtoposide·Atezolizumab·Cisplatin·Carboplatin
Merck Sharp & Dohme LLC
Phase 3
460
Hefei, Beijing, Fuzhou, Harbin, Zhengzhou, Wuhan, Changsha, Suzhou
2022-03-24
By invitation
A Follow-up Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B
NCT06707922Chronic Hepatitis B
DrugsTenofovir Alafenamide Fumarate·Peginterferon ฮฑ-2b
Xiamen Amoytop Biotech Co., Ltd.
Not applicable
350
Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Guanzhou, Harbin, Hefei
2022-03-18
Active, closed
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
NCT05239728Carcinoma, Renal Cell
DrugsBelzutifan·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
1,800
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Zhengzhou, Wuhan
2022-03-15
Active, closed
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma
NCT05201248B-Cell Non-Hodgkin Lymphoma
DrugsEpcoritamab·Vincristine·Doxorubicin·Prednisone
Genmab
Phase 1/2
49
Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Suzhou, Xuzhou
2022-03-10
Active, closed
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
NCT05100862Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma
DrugsZanubrutinib·Obinutuzumab·Lenalidomide·Rituximab
BeOne Medicines
Phase 3
799
Wuhu, Beijing, Chongqing, Fuzhou, Xiamen, Foshan, Guangzhou, Huizhou
2022-03-10
Recruiting
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
NCT05201781Multiple Myeloma
DrugCilta-cel
Janssen Research & Development, LLC
Phase 4
295
Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Xi'an
2022-03-09
Recruiting
Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer
NCT05112991Advanced Endometrial Cancer
3D Medicines (Sichuan) Co., Ltd.
Phase 2
108
Beijing, Chongqing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Yueyang
2022-03-04
Active, closed
A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection
NCT05120349Non-Small Cell Lung Cancer
DrugOsimertinib
AstraZeneca
Phase 3
390
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2022-02-21
Not yet open
the Clinical Efficacy of Robotic and Laparoscopic Radical Total Gastrectomy in Locally Advanced Middle and Upper Gastric Cancer
NCT05235932Gastric Cancer, Robotic Gastrectomy
Fujian Medical University
Not applicable
570
Fuzhou
2022-02-20
Active, closed
Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer
NCT04851613Breast Cancer
Laekna Limited
Phase 3
256
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Foshan, Guangzhou, Zhongshan
2022-02-18
Active, closed
PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer
NCT05180734Gastric or Esophagogastric Junction Adenocarcinoma
Shanghai Junshi Bioscience Co., Ltd.
Phase 3
878
Bengbu, Chizhou, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Wuwei
2022-02-10
Active, closed
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
NCT05173987Endometrial Neoplasms
DrugsTaxotere·Paraplatin·Taxol·Docetaxel
Merck Sharp & Dohme LLC
Phase 3
280
Hefei, Beijing, Chongqing, Fulingqu, Fuzhou, Guangzhou, Shantou, Zhanjiang
2022-02-03
By invitation
A Study to Test the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
NCT05076617Stereotypical Prolonged Seizures
DrugStaccato alprazolam
UCB Biopharma SRL
Phase 3
300
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Kunming
2022-02-03
Active, closed
A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)
NCT05094336Advanced MTAP-null Solid Tumors
DrugsAnvumetostat·Docetaxel
Amgen
Phase 1/2
329
Chongqing, Fuzhou, Shanghai
2022-02-01
Active, closed
Corheart 6 Left Ventricular Assist System Prospective, Multicenter, Single-arm Clinical Evaluation Trial
NCT05353816End-stage Heart Failure
Shenzhen Core Medical Technology CO.,LTD.
Not applicable
50
Beijing, Fuzhou, Guangzhou, Wuhan, Changsha, Zhengzhou, Nanjing, Suzhou
2022-01-26
Active, closed
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease
NCT05197049Crohn Disease
DrugsGuselkumab 1·Guselkumab 2·Guselkumab 3
Janssen Research & Development, LLC
Phase 3
350
Bengbu, Changsha, Changzhou, Chengdu, Chongqing, Foshan, Fuzhou, Ganzhou
2022-01-19
Recruiting
A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
NCT05851014Breast Cancer
DrugLetrozole
Genor Biopharma Co., Ltd.
Phase 3
350
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Wenzhou, Xiamen, Foshan
2022-01-14
Recruiting
A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors
NCT05170958Advanced Solid Tumor
DrugLBL-024
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2
396
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Guanzhou, Nanning
2022-01-06
Active, closed
A Phase I Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid Tumors
NCT05114759Advanced Solid Tumors
DrugSHR-A2009
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1
176
Chongqicun, Fuzhou, Guangzhou, Changsha, Nanchang, Changchun, Jinan, Xiโ€™an
2022-01-04
By invitation
CLIME-CJD: A Multimodal Study
NCT07589283Creutzfeldt-Jakob Disease (CJD) | Prion Disease
First Affiliated Hospital of Fujian Medical University
Observational
150
Fuzhou
2022-01-01
Recruiting
Validation of CAGIB Score for In-hospital Mortality of Cirrhotic Patients With Acute Gastrointestinal Bleeding
NCT04662918GastroIntestinal Bleeding
Xingshun Qi
Observational
3,000
Beijing, Fuzhou, Wuhan, Nanchang, Dalian, Shenyang, Xi'an, Jinan
2022-01-01
Active, closed
Lorlatinib Continuation Study
NCT05144997Non-Small-Cell Lung Cancer, NSCLC
DrugLorlatinib
Pfizer
Phase 4
76
Hefei, Beijing, Fuzhou, Guangzhou, Changsha, Nanjing, Changchun, Hangzhou
2021-12-28
Active, closed
Crizotinib Continuation Clinical Study
NCT05160922NSCLC, ALCL, IMT
Pfizer
Phase 4
27
Beijing, Fuzhou, Guangzhou, Changchun, Wuhou District, Hangzhou, Shanghai
2021-12-27
Active, closed
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT04819100Carcinoma, Non-Small-Cell Lung
DrugSelpercatinib
Eli Lilly and Company
Phase 3
152
Beijing, Fuzhou, Guangzhou, Harbin, Changsha, Changchun, Xi'an, Jinan
2021-12-20
Recruiting
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
NCT05067283Advanced Solid Tumors
DrugsCalderasib·Leucovorin·Cetuximab·Ivonescimab
Merck Sharp & Dohme LLC
Phase 1
830
Beijing, Fuzhou, Guangzhou, Wuhan, Changchun, Shanghai, Hangzhou
2021-12-17
Active, closed
Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)
NCT04954859Hepatitis B
DrugBepirovirsen
GlaxoSmithKline
Phase 2
360
Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Kunming, Liuzhou
2021-12-14
Active, closed
A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis
NCT05070858Generalized Myasthenia Gravis
DrugsCemdisiran·Pozelimab
Regeneron Pharmaceuticals
Phase 3
288
Beijing, Fuzhou, Guangdong, Guangzhou, Shenzhen, Haikou, Wuhan, Changsha
2021-12-14
Active, closed
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).
NCT05116189Ovarian Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms
DrugsDocetaxel·Bevacizumab·Paclitaxel·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
643
Hefei, Beijing, Fuzhou, Lanzhou, Guangzhou, Zhanjiang, Nanning, Haikou
2021-12-13
Recruiting
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
NCT04892173Carcinoma, Squamous Cell
DrugsJNJ-90301900·Cetuximab
Johnson & Johnson Enterprise Innovation Inc.
Phase 3
500
Bengbu, Changsha, Chengdu, Dongguan, Fuzhou, Guangzhou, Jinan, Linyi
2021-12-10
Recruiting
A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
NCT05077904Stereotypical Prolonged Seizures
DrugStaccato alprazolam
UCB Biopharma SRL
Phase 3
350
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Kunming
2021-12-07
Active, closed
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
NCT05152147Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
DrugsZanidatamab·Trastuzumab·Ivonescimab·Tislelizumab
Jazz Pharmaceuticals
Phase 3
920
Beijing, Bengbu, Changsha, Changzhi, Changzhou, Chengdu, Fuzhou, Guangzhou
2021-12-02
Recruiting
Prospective Cohort Study on Antibiotic Course and Efficacy After Two-stage Revision in PJI.
NCT05284318Periprosthetic Joint Infection, Anti-Bacterial Agents
First Affiliated Hospital of Fujian Medical University
Observational
500
Fuzhou
2021-12-01
Active, closed
Pediatric Spinal Muscular Atrophy (SMA) China Registry
NCT05042921Muscular Atrophy, Spinal
Biogen
Observational
600
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shenzhen, Nanning
2021-11-18
Recruiting
Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
NCT05024214Solid Tumors, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma
DrugsSunitinib·Envafolimab·Lenvatinib
3D Medicines (Sichuan) Co., Ltd.
Phase 1/2
170
Bengbu, Beijing, Fuzhou, Xiamen, Dongguan, Guangzhou, Zhuhai, Haerbin
2021-11-15
Active, closed
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer
NCT04940052Differentiated Thyroid Cancer (DTC)
DrugsDabrafenib·Trametinib
Novartis Pharmaceuticals
Phase 3
153
Fuzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Xuzhou, Changchun, Chengdu
2021-11-15
Active, closed
Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma.
NCT05176002Esophageal Neoplasm, Immunotherapy, Radiotherapy
DrugCamrelizumab
Fujian Medical University Union Hospital
Phase 1/2
25
Fuzhou
2021-11-10
Active, closed
A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations
NCT05048797Locally Advanced or Metastatic Non-Small Cell Lung Cancer
DrugsTrastuzumab deruxtecan·Pemetrexed·Cisplatin·Carboplatin
AstraZeneca
Phase 3
454
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan
2021-10-28
Recruiting
A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.
NCT07392736Solid Tumor
DrugsAL8326·Toripalimab
Advenchen Laboratories, LLC
Phase 1/2
228
Beijing, Hunan, Fuzhou, Shantou, Shaoguan, Guilin, Liuzhou, Nanning
2021-10-26
Recruiting
First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
NCT05099172Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation
Bayer
Phase 1/2
400
Beijing, Fuzhou, Harbin, Wuhan, Changsha, Nanjing, Taizhou, Jinan
2021-10-25
Active, closed
A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer
NCT04958239Neoplasms
DrugsEzabenlimab·Pembrolizumab
Boehringer Ingelheim
Phase 1
151
Bengbu, Changsha, Fuzhou, Guangzhou, Wuhan
2021-10-18
Active, closed
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05083169Multiple Myeloma
DrugsTeclistamab·Bortezomib·Pomalidomide·Daratumumab
Janssen Research & Development, LLC
Phase 3
587
Beijing, Changchun, Changshashi, Chaoyang District, Chengdu, Fuzhou, Guangzhou, Hangzhou
2021-10-14
Active, closed
Study of Sacituzumab Govitecan in Patients With Solid Tumor
NCT05119907Solid Tumor
DrugSacituzumab Govitecan
Gilead Sciences
Phase 2
53
Beijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Nanjing
2021-10-12
Recruiting
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
NCT05020236Multiple Myeloma
DrugsElranatamab·Pomalidomide·Daratumumab·Dexamethasone
Pfizer
Phase 3
893
Beijing, Fuzhou, Guangzhou, Shenzhen, Shijiazhuang, Zhengzhou, Wuhan, Nanjing
2021-10-04
Active, closed
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
NCT04975308Breast Neoplasms, Neoplasm Metastasis
DrugsImlunestrant·Exemestane·Abemaciclib·Fulvestrant
Eli Lilly and Company
Phase 3
874
Bengbu, Beijing, Fuzhou, Guangzhou, Jiangmen, Shenzhen, Zhanjiang, Zhongshan
2021-10-04
Recruiting
Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer
NCT05019690Advanced Triple Negative Breast Cancer
DrugsApatinib Mesylate·Albumin-Bound Paclitaxel
Fujian Cancer Hospital
Phase 1/2
29
Fuzhou
2021-10-01
Active, closed
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis
NCT05050136Primary Biliary Cholangitis, PBC
DrugVolixibat
Mirum Pharmaceuticals, Inc.
Phase 2
333
Fuzhou, Wuhan, Changchun, Hangzhou, Beijing
2021-09-22
Active, closed
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
NCT04965493Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsPirtobrutinib·Venetoclax·Rituximab
Loxo Oncology, Inc.
Phase 3
600
Beijing, Changsha, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Hengyang
2021-09-20
Recruiting
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
NCT04973605Relapsed/Refractory Multiple Myeloma
DrugsSonrotoclax·Carfilzomib·Pomalidomide·Daratumumab
BeOne Medicines
Phase 1/2
246
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan
2021-09-16
Recruiting
A Registered Cohort Study on Neurodegenerative Associated With Sleep Disorder.
NCT05524922Neurodegenerative Disorder
Fujian Medical University Union Hospital
Observational
500
Fuzhou
2021-09-01
Recruiting
A Registered Cohort Study on ฮฑ-Synucleinopathy
NCT05527067ฮฑ-synucleinopathy
Fujian Medical University Union Hospital
Observational
500
Fuzhou
2021-09-01
Active, closed
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
NCT04849728NASH - Nonalcoholic Steatohepatitis
Inventiva Pharma
Phase 3
1,000
Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Shenzhen, Nanning
2021-08-19
Active, closed
A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
NCT04974398Nasopharyngeal Carcinoma
DrugPenpulimab
Akeso
Phase 3
296
Hefei, Fuzhou, Xiamen, Dongguan, Guangzhou, Jiangmen, Shantou, Shenzhen
2021-08-16
By invitation
Chinese Multicenter Clinical Outcome Cohort Study of Myotonic Dystrophy Type 1 (C-DMCOS-DM1)
NCT06101940Myotonic Dystrophy 1
Huashan Hospital
Observational
1,000
Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Wuhan, Nanjing, Suzhou
2021-08-01
By invitation
Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection
NCT04762459Non-small Cell Lung Carcinoma
DrugsAlmonertinib·Pemetrexed·Cisplatin
Chinese Academy of Medical Sciences
Phase 3
606
Beijing, Changsha, Chendu, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2021-08-01
Active, closed
Newly Diagnosed Glioblastoma
NCT04959500Glioblastoma
DrugsAnlotinib hydrochloride·Temozolomide
Sun Yat-sen University
Phase 2
150
Bengbu, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Shenzhen, Zhuhai
2021-07-21
Recruiting
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
NCT04951622Myasthenia Gravis
DrugNipocalimab
Janssen Research & Development, LLC
Phase 3
199
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan
2021-07-15
Recruiting
Compare Continuation of Original Targeted Therapy With Trastuzumab Combined With Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-pCR Patients With HER2 Positive Early Breast Cancer
NCT05292742Breast Cancer, Adjuvant Therapy
DrugsPertuzumab/Trastuzumab·Pyrotinib·Trastuzumab·Capecitabine
Fujian Medical University Union Hospital
Phase 2
206
Fuzhou
2021-07-02
Active, closed
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
NCT04886804Neoplasm Metastasis, Non-Small Cell Lung Cancer
DrugZongertinib
Boehringer Ingelheim
Phase 1
554
Beijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Harbin, Nanning, Shanghai
2021-07-02
Active, closed
Characteristics of Vaginal and Intestinal Microbiota and Cervical HPV Infection
NCT05003505Intestinal Microbiota, Vaginal Microbiota, HPV Infection
Fujian Maternity and Child Health Hospital
Observational
651
Fuzhou, Ningde, Quanzhou, Xiamen, Zhangzhou, Foshan, Shenzhen, Wuhan
2021-07-01
Active, closed
A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy
NCT04629248Primary Membranous Nephropathy
DrugsDiphenhydramine·Acetaminophen·Tacrolimus·Methylprednisolone
Hoffmann-La Roche
Phase 3
142
Hangzhou, Beijing, Chengdu, Fuzhou, Guangzhou, Shanghai, Wuhan, Xi'an
2021-06-25
Active, closed
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
NCT04793958Advanced Colorectal Cancer, Metastatic Colorectal Cancer
DrugsMRTX849·Erbitux·MFOLFOX6·Folfiri
Mirati Therapeutics Inc.
Phase 3
461
Bengbu, Hefei, Beijing, Fuzhou, Guangzhou, Shenzhen, Nanning, Zhengzhou
2021-06-24
Recruiting
Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer
NCT04790305Carcinoma Breast, Triple-negative Breast Cancer, Invasive Ductal Carcinoma, Breast
Fudan University
Phase 4
1,072
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Harbin, Zhengzhou
2021-06-18
Recruiting
Pyrotinib Combined With Trastuzumab for Maintenance Therapy After First-line TH (P) Therapy for HER2+ABC
NCT06754059HER2-positive Breast Cancer
zhangjie
Observational
60
Fuzhou
2021-06-01
Active, closed
A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer
NCT04854668Metastatic Colorectal Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
748
Chizhou, Fuzhou, Hefei, Xuancheng, Beijing, Chongqing, Xiamen, Lanzhou
2021-05-27
Active, closed
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
NCT04704934Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
DrugsRamucirumab·Trastuzumab deruxtecan·Paclitaxel
Daiichi Sankyo
Phase 3
490
Heifi, Fuzhou, Xiamen, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Changshan
2021-05-21
Rows per page Showing 801–900 of 1018
Previous 7 8 9 10 11 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/city/fuzhou?page=9

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,018 of those studies with a site in Fuzhou.

How many clinical trials are recruiting in Fuzhou?

594 of the 1,018 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 114 have not yet opened recruitment, 287 are active but closed to new participants, and 23 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.